UroGen Pharma Ltd.
URGN | NASDAQ
$43.20
-$0.05 (-0.12%)
At close: Sep 21, 2026, 4:00 PM ET
$44.20
+$1 (+2.31%)
After-hours:
Sep 21, 2026, 7:30 PM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 109.79M | 90.4M | 82.71M | 64.36M | 48.04M | 11.8M |
Cost of Revenue | 12.45M | 8.88M | 9.36M | 7.65M | 5.16M | 1.01M |
Gross Profit | 97.34M | 81.52M | 73.35M | 56.7M | 42.89M | 10.79M |
Operating Income | -124.86M | -96.78M | -65.54M | -79.04M | -92.29M | -126.74M |
Interest Income | 5.97M | 8.9M | 2.64M | 938K | 365K | 1.99M |
Pretax Income | -153.42M | -124.04M | -98.32M | -108.03M | -109.37M | -125.11M |
Net Income | -153.49M | -126.87M | -102.24M | -109.78M | -110.82M | -128.48M |
Selling & General & Admin | 155.1M | n/a | 93.27M | 82.84M | n/a | 90.22M |
Research & Development | 67.11M | 57.15M | 45.61M | 52.91M | 47.64M | 47.31M |
Other Expenses | n/a | 121.15M | n/a | n/a | 87.54M | n/a |
Operating Expenses | 222.2M | 178.3M | 138.89M | 135.74M | 135.18M | 137.53M |
Interest Expense | 33.85M | 12.52M | 14.72M | 8.44M | 17.44M | 357K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 234.65M | 187.18M | 148.25M | 143.4M | 140.33M | 138.54M |
Income Tax Expense | 78K | 2.83M | 3.92M | 1.76M | 1.45M | 3.37M |
Shares Outstanding (Basic) | 48.12M | 42.88M | 28.83M | 22.81M | 22.35M | 21.78M |
Shares Outstanding (Diluted) | 48.12M | 42.88M | 28.83M | 22.81M | 22.35M | 21.78M |
EPS (Basic) | -3.19 | -2.96 | -3.55 | -4.79 | -4.96 | -5.90 |
EPS (Diluted) | -3.19 | -2.96 | -3.55 | -4.79 | -4.96 | -5.90 |
EBITDA | -135.66M | -95.35M | -60.35M | -76.21M | -108.54M | -122.71M |
EBIT | -138.07M | -95.68M | -62.06M | -78.03M | -109.37M | -124.75M |
Depreciation & Amortization | 2.41M | 329K | 1.71M | 1.82M | 831K | 2.04M |
Add to Watchlist
Select watchlists to add or remove URGN